Inovio Ramps Up Production of Its Coronavirus Vaccine Candidate

Inovio Pharmaceuticals' (NASDAQ:INO) SARS-CoV-2 vaccine candidate, INO-4800, is only in phase 1 development, but the biotech is already preparing to produce it at scale through a partnership with the German contract manufacturer Richter-Helm BioLogics.